p57 Kip2 Antibody (Mouse mAb) [B21E12]

CatNo: F7318

    Application: Reactivity:
    • Lane 1: SH-SY5Y
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    キーポイント

    WB
    転写条件(ウェット): 200 mA, 60 min
    90秒以上の露光(暴露)を推奨します。

    使用情報

    Dilution
    1:50-1:500
    1:400-1:800
    Application
    WB, IHC
    Source
    Mouse Monoclonal Antibody
    Reactivity
    Human, Mouse
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    32 kDa ~57 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。
    ポジティブコントロール Human colon carcinoma; Jurkat cells; SH-SY5Y cells; Neuro-2a cells
    ネガティブコントロール

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/Nuclear Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/Nuclear Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/Nuclear Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 60 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use primary antibody dilution buffer to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:500), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system. (Exposure time of at least 90s is recommended)
    IHC
    Experimental Protocol:
     
    Deparaffinization/Rehydration
    1. Deparaffinize/hydrate sections:
    2. Incubate sections in three washes of xylene for 5 min each.
    3. Incubate sections in two washes of 100% ethanol for 10 min each.
    4. Incubate sections in two washes of 95% ethanol for 10 min each.
    5. Wash sections two times in dH2O for 5 min each.
    6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.
     
    Staining
    1. Wash sections in dH2O three times for 5 min each.
    2. Incubate sections in 3% hydrogen peroxide for 10 min.
    3. Wash sections in dH2O two times for 5 min each.
    4. Wash sections in wash buffer for 5 min.
    5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.
    6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.
    7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.
    8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.
    9. Wash sections three times with wash buffer for 5 min each.
    10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.
    11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.
    12. Immerse slides in dH2O.
    13. If desired, counterstain sections with hematoxylin.
    14. Wash sections in dH2O two times for 5 min each.
    15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.
    16. Mount sections with coverslips and mounting medium.
     

    Datasheet & SDS

    生物学的記述

    Specificity
    p57 Kip2 Antibody (Mouse mAb) [B21E12] detects endogenous levels of total p57 Kip2 protein.
    タンパク質の局在
    細胞核
    Uniprot ID
    P49918
    Clone
    B21E12
    Synonym(s)
    Beckwith Wiedemann syndrome (WBS); Cyclin-dependent kinase inhibitor p57; IMAGE; p57 Kip2; p57Kip2; AL024410; BWCR; BWS; CDKI; CDKN1C; KIP2; p57; p57(kip2); p57Kip2; WBS
    Background
    p57 Kip2 (CDKN1C) belongs to the Cip/Kip family of cyclin‑dependent kinase inhibitors together with p21 and p27, and acts as a potent negative regulator of cell proliferation that is encoded by a maternally expressed imprinted gene at chromosome 11p15.5 within a growth‑control domain frequently altered in imprinting disorders and cancer. The protein contains an N‑terminal CDK inhibitory domain that is conserved across Cip/Kip members and binds G1 cyclin–CDK complexes including cyclin D/CDK4–6 and cyclin E/CDK2, enforcing G1 arrest, followed by a unique central proline‑rich region that interacts with the LIM‑kinase LIMK1 and a C‑terminal QT domain that associates with and inhibits JNK/SAPK, creating a modular architecture that couples classical cell‑cycle inhibition with direct control of cytoskeletal dynamics and stress‑activated kinase signaling. The LIMK1‑binding central region localizes LIMK1 in the nucleus and modifies cofilin phosphorylation and actin filament organization, linking p57 Kip2 to regulation of cell shape, migration, and neuronal process outgrowth in addition to its role in proliferation control. The QT domain binds JNK/SAPK and dampens its kinase activity, influencing apoptosis and differentiation programs downstream of stress and developmental cues, while p57 Kip2 also modulates genome expression more broadly through reported interactions with transcriptional regulators and chromatin‑associated complexes, providing a route by which CDK inhibition is integrated with lineage‑specific transcriptional outputs. Expression is tightly developmentally regulated and far more restricted than other Cip/Kip proteins, with high levels in placenta, developing brain, muscle, and hematopoietic compartments, and induction by pathways such as TGF‑β/Smad in hematopoietic stem cells where p57 Kip2 enforces quiescence, contrasted with TGF‑β‑driven degradation in osteoblasts, illustrating context‑dependent integration of extracellular signals. Protein stability is controlled by phosphorylation‑dependent ubiquitination: phosphorylation on threonine 310 promotes recognition by the SCF–Skp2 E3 ubiquitin ligase complex, targeting p57 Kip2 for proteasomal degradation in a mechanism analogous to Thr187‑dependent turnover of p27, and placing p57 Kip2 under direct control of mitogenic CDK–Skp2 circuits. In addition to its central function in restraining G1–S transition, p57 Kip2 plays critical roles at early steps of cell and tissue differentiation, particularly in embryogenesis, neuronal development, and erythropoiesis, where its presence coordinates cell‑cycle exit with acquisition of differentiated phenotypes. The protein influences cell migration through LIMK1‑dependent reorganization of the actin cytoskeleton, and emerging evidence indicates that p57 Kip2 also participates in regulation of mitochondrial apoptotic pathways, with specific phosphorylation patterns modulating its subcellular localization between nucleus and cytoplasm and thereby shifting its impact on survival versus death decisions. CDKN1C is frequently downregulated by genetic, epigenetic, or imprinting alterations in a broad spectrum of epithelial and non‑epithelial malignancies, consistent with its classification as a tumor suppressor, and loss or reduction of p57 Kip2 correlates with enhanced proliferation, invasion, and metastatic behavior, while enforced expression suppresses tumorigenic traits in multiple models. Germline loss‑of‑function mutations and epimutations affecting CDKN1C contribute to Beckwith–Wiedemann syndrome, characterized by somatic overgrowth and elevated childhood tumor risk, whereas distinct gain‑of‑function mutations underlie IMAGe syndrome with severe growth restriction, illustrating that finely tuned p57 Kip2 dosage is required for normal human growth control and that both reduced and excessive activity are pathogenic.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください